12 Set-It-and-Forget-It Stocks to Buy Now

Page 6 of 10

5. Abbott Laboratories (NYSE:ABT)

Market Cap as of Sept 29, 2025: $232.44 Billion

Abbott Laboratories (NYSE:ABT) enters our list of 12 set-it-and-forget-it stocks to buy now. Amid a positive second quarter and a top executive sale, the company gains an expansion opportunity from Medtronic.

Abbott Laboratories (NYSE:ABT) reported a 6.9% increase in sales for the second quarter of 2025. The earnings report, announced on July 17, 2025, also highlighted an Adjusted EPS of $1.26, which beat the consensus estimates. The company is also making progress in its biosimilars portfolio and anticipates multiple launches in 2026.

Following the second quarter results, the company’s Executive Vice President and Chief Financial Officer, Philip P Boudreau, sold 5,550 shares on August 11, 2025, in a transaction valued at $746,752, signaling negative sentiment. However, on September 2, 2025, the FDA cleared Medtronic’s MiniMed 780G system. The system involves an integration with Abbott Laboratories (NYSE:ABT)’s Instinct sensor. It presents the company with an opportunity to expand its diabetes technology.

With a significant market cap of $232.44 billion, reflecting a strong foothold in the industry, Abbott Laboratories (NYSE:ABT) is a solid choice for long-term, low-maintenance investors.

Abbott Laboratories (NYSE:ABT) is a diversified global healthcare leader. With headquarters in Illinois, the company has been in operation since 1888. It develops, manufactures, and sells a wide range of medical devices, diagnostics, nutritional products, and established branded generic pharmaceuticals worldwide.

Page 6 of 10